Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 23, 2025 12:21 ET | Source: Research and Markets

Effective Management of Supply Chain Risk: 2-Day Online Training Course (Oct 16th-17th, 2025) - Navigate Supply Chain Risks with Proactive Management Techniques

Dublin, Sept. 23, 2025 (GLOBE NEWSWIRE) -- The "Effective Management of Supply Chain Risk Training Course (Oct 16th - Oct 17th, 2025)" has been added to ResearchAndMarkets.com's offering. "A...
September 19, 2025 10:10 ET | Source: Janssen Cilag International NV

TREMFYA (guselkumab) receives positive CHMP opinion for subcutaneous induction regimen in ulcerative colitis, a first for an IL-23 inhibitor

Recommendation based on the findings from the Phase 3 ASTRO study in ulcerative colitis.1,2,3 Guselkumab has the potential to become the first IL-23 inhibitor to offer both subcutaneous and...
September 11, 2025 07:56 ET | Source: Janssen Cilag International NV

Johnson & Johnson seeks first European Medicines Agency approval for icotrokinra aiming to transform the plaque psoriasis treatment paradigm

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints....
September 07, 2025 03:28 ET | Source: Janssen Cilag International NV

Data published in The New England Journal of Medicine demonstrate RYBREVANT®▼(amivantamab) plus LAZCLUZE®▼ (lazertinib) could re-set survival expectations in first-line EGFR-mutated advanced lung cancer

Chemotherapy-free combination regimen has the potential to usher in new era for first-line treatment, with median overall survival projected to exceed four years, surpassing monotherapy TKI...
September 06, 2025 03:10 ET | Source: Janssen Cilag International NV

RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer

New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs1 BEERSE, BELGIUM , Sept. 06, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag...
September 04, 2025 03:00 ET | Source: Johnson & Johnson MedTech

Johnson & Johnson Launches First Daily Disposable Toric Contact Lens Designed to Deliver on the Specific Needs of Low and High Astigmatic Patients in United Kingdom and Ireland (UKI)

World’s #1 Selling Contact Lens Brand ACUVUE®1 Brings Pioneering Innovation For Astigmatic Patients, Providing Visual Clarity And Comfort+2 The First^^ Toric Lens to have an Optimised Design...
August 18, 2025 04:25 ET | Source: Research and Markets

3D Printing Plastics Market Report 2025 | 3D Printing Plastics Market Forecast to Reach USD 5.39 Billion by 2030

Dublin, Aug. 18, 2025 (GLOBE NEWSWIRE) -- The "3D Printing Plastics Market by Type (Photopolymer, ABS, Polyamide, PLA, PETG), Form (Filament, Liquid, Powder), Application (Prototyping,...
August 07, 2025 01:00 ET | Source: Nordecon

2025 II quarter and 6 months consolidated interim report (unaudited)

The Estonian economy continues to grow slowly, with the latest forecasts estimating annual economic growth at 1.2%. The construction market is showing signs of stabilisation. Within the buildings...
August 06, 2025 13:05 ET | Source: Research and Markets

3D Printed Prosthetics Industry Worth $3.1 Billion by 2034, Eyeing 7.5% CAGR Through 2025-2034

Dublin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The "3D Printed Prosthetics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" has been added to ResearchAndMarkets.com's...
July 31, 2025 11:53 ET | Source: Foresight Ventures VCT plc

Final Results

FORESIGHT VENTURES VCT PLCLEI: 213800R88MRC4Y3OIW8631 July 2025 CORRECTION - FINAL RESULTS FOR THE YEAR ENDED 31 MARCH 2025 The announcement of the Company’s Final Results, which was originally made...